Mouse anti-Human CD262/DR5 Monoclonal Antibody | anti-CD262/DR5 antibody

CD262/DR5

Cat. Num. AAA215274

• Reactivity: Human
• Applications: Immunohistochemistry
• Purity: Purified Ab with BSA and Azide at 200ug/ml OR Purified Ab WITHOUT BSA and Azide at 1.0mg/ml
• Synonyms: CD262/DR5, Antibody; CD262/DR5; Fas like protein; Apoptosis inducing protein TRICK2A/2B; Apoptosis inducing receptor TRAIL R2; Cytotoxic TRAIL receptor 2; Death domain containing receptor for TRAIL/Apo 2L; Death receptor 5 (DR5); p53 regulated DNA damage inducible cell death receptor (killer); TNF related apoptosis inducing ligand receptor 2 (TRICK2; Tumor necrosis factor receptor like protein ZTNFR9; Tumor necrosis factor receptor superfamily member 10B; ZTNFR9; anti-CD262/DR5 antibody

• Host: Mouse
• Reactivity: Human
• Clonality: Monoclonal
• Isotype: IgG1, kappa
• Clone Number: DR5/3381
• Specificity: Tumor necrosis factor (TNF) is a pleiotropic cytokine whose function is mediated by two distinct cell surface receptors, designated TNF-R1 and TNF-R2, which are expressed on most cell types. TNF function is primarily mediated through TNF-R1 signaling. Both receptors belong to the growing TNF receptor superfamily which includes Fas antigen and CD40. TNF-R1 contains a cytoplasmic motif, termed the death domain, that has been found to be necessary for the transduction of the apoptotic signal. The death domain is also found in several other receptors, including Fas, DR2 (or TRUNDD), DR3 (death receptor 3), DR4 and DR5. TRUNDD, DR4 and DR5 are receptors for the apoptosis-inducing cytokine TRAIL. A non-death domain-containing receptor, designated decoy receptor (DcR1 or TRID), also specifically associates with TRAIL and may play a role in cellular resistance to apoptotic stimuli.
• Purity/Purification: Purified Ab with BSA and Azide at 200ug/ml OR Purified Ab WITHOUT BSA and Azide at 1.0mg/ml
• Form/Format: 200ug/ml of Ab Purified from Bioreactor Concentrate by Protein A/G. Prepared in 10mM PBS with 0.05% BSA & 0.05% azide. Also available WITHOUT BSA & azide at 1.0mg/ml.

• Applicable Applications for anti-CD262/DR5 antibody: IHC (Immunohistochemistry)
• Positive Control: Human colon cancer or endometrial tissue (IHC).
• Immunogen: Recombinant human DR5 protein fragment (around aa266-393) (exact sequence is proprietary)
• Cellular Localization: Cell Surface
• Hu-chromosome Location: 8p21.3
• Preparation and Storage: Antibody with azide: store at 2 to 8 degree C.; Antibody without azide: store at -20 to -80 degree C.; Antibody is stable for 24 months. Non-hazardous. No MSDS required.

Application Data

(Analysis of Protein Array containing >19,000 full-length human proteins using DR5 Mouse Monoclonal Antibody (DR5/3381) Z- and S- Score: The Z-score represents the strength of a signal that a monoclonal antibody (Monoclonal Antibody) (in combination with a fluorescently-tagged anti-IgG secondary antibody) produces when binding to a particular protein on the HuProtTM array. Z-scores are described in units of standard deviations (SD’s) above the mean value of all signals generated on that array. If targets on HuProtTM are arranged in descending order of the Z-score, the S-score is the difference (also in units of SD’s) between the Z-score. S-score therefore represents the relative target specificity of a Monoclonal Antibody to its intended target. A Monoclonal Antibody is considered to specific to its intended target, if the Monoclonal Antibody has an S-score of at least 2.5. For example, if a Monoclonal Antibody binds to protein X with a Z-score of 43 and to protein Y with a Z-score of 14, then the S-score for the binding of that Monoclonal Antibody to protein X is equal to 29.)

IHC (Immunohiostchemistry)

(Formalin-fixed, paraffin-embedded human breast carcinoma stained with DR5 Mouse Monoclonal Antibody (DR5/3381).)

IHC (Immunohistochemistry)

(Formalin-fixed, paraffin-embedded human colon carcinoma stained with DR5 Mouse Monoclonal Antibody (DR5/3381).)

References

Jiang, Q., et al. 2012. Apoptosis-inducing effect of the DR5 monoclonal antibody, D-6, alone or in combination with cisplatin, on A2780 ovarian cancer cells. Mol. Med. Rep. 6: 316-320.